Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trialTong Li, Zhongsheng Tong, Tao Sun et al.|Nature Communications|2025Cited by 10
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.Binghe Xu, Qingyuan Zhang, Yang Luo et al.|Journal of Clinical Oncology|2023Cited by 4